![](/img/cover-not-exists.png)
Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients
de Oliveira, Mariana B., Fook-Alves, Veruska L., Eugenio, Angela I.P., Fernando, Rodrigo C., Sanson, Luiz Felipe G., de Carvalho, Mariana F., Braga, Walter M.T., Davies, Faith E., Colleoni, Gisele W.BVolume:
403
Language:
english
Journal:
Cancer Letters
DOI:
10.1016/j.canlet.2017.06.016
Date:
September, 2017
File:
PDF, 1.90 MB
english, 2017